AB12319

AB12319 is a preclinical-stage small molecule drug developed by AB Science. It belongs to the class of microtubule destabilizer agents (MDAs) and is part of a platform focused on haemato-oncology. The primary therapeutic area for AB12319 is hematologic neoplasms, including various blood cancers. While detailed mechanistic data specific to AB12319 are not publicly disclosed, it is closely related in development context to another MDA from the same company, AB8939, which acts by destabilizing microtubules and targeting cancer stem cells via inhibition of aldehyde dehydrogenase (ALDH). The main goal for this class of drugs is to overcome multidrug resistance mechanisms common in hematologic malignancies and improve outcomes in diseases such as acute myeloid leukemia (AML)[1][4][7].